PDF herunterladen
Semin Thromb Hemost 2003; 29: 013-016
DOI: 10.1055/s-2003-45412
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Low-Molecular-Weight Heparins: Beyond Thrombosis in the Management of the Cancer Patient

Ajay K. Kakkar
  • Department of Surgical Oncology and Technology, Imperial College, Hammersmith Hospital, London, United Kingdom
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Dezember 2003 (online)

    Lizenzen und Reprints

ABSTRACT

Thrombosis is a common complication in patients with cancer and large, retrospective population-based studies indicate that cancer patients with clinical venous thromboembolism have a poorer prognosis than those without. The risk of thrombosis appears to differ between different tumor types. Beyond the important impact that fatal pulmonary embolism may have on cancer outcome, the activated coagulation serine proteases generated by cancer cells through the peritumor activation of blood coagulation pathways are able to interact with cell surface protease receptors. These, in turn, mediate several cellular events resulting in important phenotypic alterations in tumor cell behavior.

KEYWORDS

Low-molecular-weight heparin - thromboembolism - cancer

REFERENCES

  • 1 Shen V S, Pollak E W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?.  South Med J . 1980;  73 841-843
    PubMedGoogle Scholar
  • 2 Levitan N, Dowlati A, Remick S. et al . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.  Medicine (Baltimore) . 1999;  78 285-291
    CrossrefPubMedGoogle Scholar
  • 3 Sorensen H T, Mellemkjaer L, Olsen J H, Baron J A. Prognosis of cancers associated with venous thromboembolism.  N Engl J Med . 2000;  343 1846-1850
    CrossrefPubMedGoogle Scholar
  • 4 Thodiyil P A, Kakkar A K. Variation in relative risk of venous thromboembolism in different cancers.  Thromb Haemost . 2002;  87 1076-1077
    PubMedGoogle Scholar
  • 5 Kakkar A K, Lemoine N R, Scully M F, Tebbutt S, Williamson R C. Tissue factor expression correlates with histological grade in human pancreatic cancer.  Br J Surg . 1995;  82 1101-1104
    CrossrefPubMedGoogle Scholar
  • 6 Kakkar A K, Chinswangwatanakul V, Lemoine N R, Tebbutt S, Williamson R C. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma.  Br J Surg . 1999;  86 890-894
    CrossrefPubMedGoogle Scholar
  • 7 Zhang Y, Deng Y, Luther T. et al . Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.  J Clin Invest . 1994;  94 1320-1327
    Google Scholar
  • 8 Mueller B M, Reisfeld R A, Edgington T S, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis.  Proc Natl Acad Sci USA . 1992;  89 11832-11836
    PubMedGoogle Scholar
  • 9 Taniguchi T, Kakkar A K, Tuddenham E G, Williamson R C, Lemoine N R. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.  Cancer Res . 1998;  58 4461-4467
    PubMedGoogle Scholar
  • 10 Ott I, Fischer E G, Miyagi Y, Mueller B M, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280.  J Cell Biol . 1998;  140 1241-1253
    Google Scholar
  • 11 Riewald M, Kravchenko V V, Petrovan R J. et al . Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1.  Blood . 2001;  97 3109-3116
    Google Scholar
  • 12 Even-Ram S, Uziely B, Cohen P. et al . Thrombin receptor overexpression in malignant and physiological invasion processes.  Nat Med . 1998;  4 909-914
    PubMedGoogle Scholar
  • 13 Sampson M T, Kakkar A K. Coagulation proteases and human cancer.  Biochem Soc Trans . 2002;  30 201-207
    PubMedGoogle Scholar
  • 14 Green D, Hull R D, Brant R, Pineo G F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin [letter].  Lancet . 1992;  339 1476
    PubMedGoogle Scholar
  • 15 Siragusa S, Cosmi B, Piovella R, Hirsh J, Ginsberg J S. Low-molecular-weight-heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.  Am J Med . 1996;  100 269-277
    CrossrefPubMedGoogle Scholar
  • 16 Hettiarachchi R J, Smorenburg S M, Ginsberg J, Levine M, Prins M H, Büller H R. Do heparins do more than just treat thrombosis?.  <~>The influence of heparins on cancer spread. Thromb Haemost . 1999;  82 947-952
    PubMedGoogle Scholar
  • 17 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.  Ann Intern Med . 1999;  130 800-809
    CrossrefPubMedGoogle Scholar
  • 18 Kakkar A K, Kadziola Z, Williamson R C, Levine M, Low V, Lemoine N R. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer.  Blood . 2002;  100 148A
    CrossrefPubMedGoogle Scholar
  • 19 Lee A Y, Levine M N, Baker R I. et al . Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.  N Engl J Med . 2003;  349 146-153
    CrossrefPubMedGoogle Scholar
  • 20 Levine M N, Lee A Y, Kakkar A K. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.  J Thromb Haemost . 2003;  1 1456-1463
    CrossrefPubMedGoogle Scholar
      >